Fig.1



4mg twice weekly
4wk on
Grade 3
maculopapular rash
3.2mg twice weekly
4wk on
Grade 3
facial rash
3.2mg twice weekly
3wk on/ 1wk off
On going
% Change from the baseline
0
-20
-40
-60
-80
0
4
8
12
16
20
24
28
32
36
40
44
Cycle
0
-29
-39
-48
-58
-58
-61
-61
-61
-61
-61
-61
-68
-68
-68
-58
-68

Fig.2




Cycle 1
Cycle 2
Cycle 3
Cycle 4
w1
w2
w3
w4
4mg Twice weekly
08-Jan
05-Feb
02-Apr
Efficacy
CT scan (-54%) Partial Response
CT scan (-58%) Partial Response
Safety
diarrhoea
Grade 2
Grade 1
Grade 2
acneiform rash
Grade 2
Grade 3
Decided to introduce 3wk on/ 1wk off schedule

Fig.3



Treatment of a subject is started at 4 mg twice weekly.

- If a drug-related adverse event (e.g., skin rash, diarrhoea, or creatine phosphokinase (CPK) elevation) of Grade 3 occurs, the dose level is reduced to 3.2 mg twice weekly. If the subject experiences a drug-related Grade 3 adverse event despite the reduction in the dose level, the dose intensity can be reduced to 3.2 mg twice weekly on a 3 weeks on/ 1 week off schedule.
- If a drug-related adverse event (e.g., skin rash, diarrhoea, or CPK elevation) of Grade 2 occurs, the dose intensity is reduced to 4 mg twice weekly on a 3 weeks on/ 1 week off schedule. If the subject experiences a drug-related Grade 3 adverse event despite the reduction in the dose intensity, the dose level can be reduced to 3.2 mg twice weekly on a 3 weeks on/ 1 week off schedule.

If the adverse events improve, the dose level and/or intensity can be reverted to the previous dose level and/or intensity based on the judgment of the physician or veterinarian.